Aebersold Ruedi, Anderson Leigh, Caprioli Richard, Druker Brian, Hartwell Leland, Smith Richard
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, North, PO Box 19024, Seattle, WA 98109-1024, USA.
J Proteome Res. 2005 Jul-Aug;4(4):1104-9. doi: 10.1021/pr050027n.
Biomarkers for cancer risk, early detection, prognosis, and therapeutic response promise to revolutionize cancer management. Protein biomarkers offer tremendous potential in this regard due to their great diversity and intimate involvement in physiology. An effective program to discover protein biomarkers using existing technology will require team science, an integrated informatics platform, identification and quantitation of candidate biomarkers in disease tissue, mouse models of disease, standardized reagents for analyzing candidate biomarkers in bodily fluids, and implementation of automation. Technology improvements for better fractionation of the proteome, selection of specific biomarkers from complex mixtures, and multiplexed assay of biomarkers would greatly enhance progress.
用于癌症风险、早期检测、预后和治疗反应的生物标志物有望彻底改变癌症管理。蛋白质生物标志物因其多样性以及在生理学中的密切参与，在这方面具有巨大潜力。利用现有技术发现蛋白质生物标志物的有效计划将需要团队合作、集成信息学平台、对疾病组织和疾病小鼠模型中的候选生物标志物进行鉴定和定量、用于分析体液中候选生物标志物的标准化试剂以及自动化的实施。改进蛋白质组分离、从复杂混合物中选择特定生物标志物以及对生物标志物进行多重检测的技术将极大地推动进展。
